Trials / Completed
CompletedNCT00211523
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- BioWest Therapeutics Inc · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBI 226 Acne Solutions |
Timeline
- Start date
- 2000-10-01
- Completion
- 2001-09-01
- First posted
- 2005-09-21
- Last updated
- 2005-09-21
Source: ClinicalTrials.gov record NCT00211523. Inclusion in this directory is not an endorsement.